Effect of the loss of the type III TGF beta receptor during tumor progression on tumor microenvironment: Preclinical development of TGF beta inhibition and TGF beta-related biomarkers to enhance immunotherapy efficacy.
Hanks, BA; Holtzhausen, A; Gimpel, P; Jamieson, R; Campbell, OM; Sun, L; Augustine, CK; Tyler, DS; Osada, T; Morse, M; Ling, LE; Lyerly, HK; Blobe, GC
Volume / Issue
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference Start Date
Conference End Date